Glenmark Pharma USA Launches Calcium Gluconate Injection USP

Glenmark Pharmaceuticals Inc., USA has announced the launch of Calcium Gluconate Injection USP in multiple dosage forms: 1,000 mg/10 mL, 5,000 mg/50 mL Single-Dose Vials, and 10,000 mg/100 mL Pharmacy Bulk Package. The product is bioequivalent and therapeutically equivalent to Fresenius Kabi USA's Calcium Gluconate Injection. The U.S. market for this injection achieved approximately $69.9 million in sales for the 12 months ending June 2026, according to IQVIA data. This launch strengthens Glenmark's U.S. injectables business and hospital portfolio, aligning with their strategy to build a differentiated and sustainable injectables business.